InBody Co.,Ltd (041830.KQ)
KRW 23400.0
(0.43%)
KRW 23400.0
(0.43%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 170.35 Billion KRW | 6.47% |
| 2022 | 160 Billion KRW | 16.08% |
| 2021 | 137.83 Billion KRW | 28.67% |
| 2020 | 107.12 Billion KRW | -8.49% |
| 2019 | 117.05 Billion KRW | 17.49% |
| 2018 | 99.63 Billion KRW | 6.84% |
| 2017 | 93.25 Billion KRW | 16.79% |
| 2016 | 79.84 Billion KRW | 15.81% |
| 2015 | 68.94 Billion KRW | 40.88% |
| 2014 | 48.94 Billion KRW | 33.04% |
| 2013 | 36.78 Billion KRW | 10.7% |
| 2012 | 33.23 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 48.42 Billion KRW | 15.55% |
| 2024 Q2 | 50.24 Billion KRW | 3.74% |
| 2023 Q2 | 40.66 Billion KRW | -5.5% |
| 2023 Q1 | 43.02 Billion KRW | -0.13% |
| 2023 FY | 170.35 Billion KRW | 6.47% |
| 2023 Q3 | 44.75 Billion KRW | 10.06% |
| 2023 Q4 | 41.91 Billion KRW | -6.35% |
| 2022 Q3 | 38.89 Billion KRW | -1.36% |
| 2022 Q1 | 38.6 Billion KRW | 1.57% |
| 2022 FY | 160 Billion KRW | 16.08% |
| 2022 Q4 | 43.08 Billion KRW | 10.78% |
| 2022 Q2 | 39.42 Billion KRW | 2.14% |
| 2021 Q4 | 38 Billion KRW | 15.02% |
| 2021 Q1 | 33.03 Billion KRW | 14.2% |
| 2021 FY | 137.83 Billion KRW | 28.67% |
| 2021 Q2 | 33.75 Billion KRW | 2.16% |
| 2021 Q3 | 33.04 Billion KRW | -2.1% |
| 2020 Q1 | 27.82 Billion KRW | -11.1% |
| 2020 Q3 | 29.31 Billion KRW | 39.27% |
| 2020 Q4 | 28.93 Billion KRW | -1.32% |
| 2020 FY | 107.12 Billion KRW | -8.49% |
| 2020 Q2 | 21.05 Billion KRW | -24.35% |
| 2019 Q4 | 31.3 Billion KRW | 13.29% |
| 2019 Q3 | 27.62 Billion KRW | -6.78% |
| 2019 FY | 117.05 Billion KRW | 17.49% |
| 2019 Q1 | 28.49 Billion KRW | 3.06% |
| 2019 Q2 | 29.63 Billion KRW | 4.02% |
| 2018 Q1 | 21.74 Billion KRW | -19.27% |
| 2018 Q3 | 25.01 Billion KRW | -0.84% |
| 2018 Q2 | 25.22 Billion KRW | 16.01% |
| 2018 FY | 99.63 Billion KRW | 6.84% |
| 2018 Q4 | 27.64 Billion KRW | 10.52% |
| 2017 FY | 93.25 Billion KRW | 16.79% |
| 2017 Q4 | 26.93 Billion KRW | 10.2% |
| 2017 Q2 | 22.21 Billion KRW | 12.97% |
| 2017 Q1 | 19.66 Billion KRW | -2.4% |
| 2017 Q3 | 24.44 Billion KRW | 10.04% |
| 2016 Q4 | 20.14 Billion KRW | 12.01% |
| 2016 FY | 79.84 Billion KRW | 15.81% |
| 2016 Q3 | 17.98 Billion KRW | -5.4% |
| 2016 Q2 | 19.01 Billion KRW | -16.26% |
| 2016 Q1 | 22.7 Billion KRW | 12.12% |
| 2015 Q4 | 20.25 Billion KRW | 10.13% |
| 2015 FY | 68.94 Billion KRW | 40.88% |
| 2015 Q1 | 15.09 Billion KRW | 17.04% |
| 2015 Q2 | 15.21 Billion KRW | 0.83% |
| 2015 Q3 | 18.38 Billion KRW | 20.83% |
| 2014 Q1 | 11.97 Billion KRW | 26.72% |
| 2014 Q2 | 12.59 Billion KRW | 5.14% |
| 2014 Q3 | 11.46 Billion KRW | -8.94% |
| 2014 Q4 | 12.89 Billion KRW | 12.43% |
| 2014 FY | 48.94 Billion KRW | 33.04% |
| 2013 Q1 | 8.93 Billion KRW | 7.1% |
| 2013 Q4 | 9.45 Billion KRW | 5.76% |
| 2013 FY | 36.78 Billion KRW | 10.7% |
| 2013 Q2 | 9.46 Billion KRW | 5.88% |
| 2013 Q3 | 8.93 Billion KRW | -5.52% |
| 2012 Q3 | 7.86 Billion KRW | 0.0% |
| 2012 Q4 | 8.34 Billion KRW | 6.07% |
| 2012 FY | 33.23 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 355.84 Billion KRW | 52.128% |
| Curexo Inc. | 72.88 Billion KRW | -133.735% |
| Seegene, Inc. | 367.37 Billion KRW | 53.63% |
| i-SENS, Inc. | 265.12 Billion KRW | 35.746% |
| Ray Co., Ltd. | 145.88 Billion KRW | -16.773% |
| Gencurix Inc. | 2.6 Billion KRW | -6451.17% |
| Sugentech Inc. | 7.13 Billion KRW | -2288.445% |
| L&C Bio Co., Ltd | 68.86 Billion KRW | -147.353% |